Clik here to view.
Astellas Launches DigiTx Partners, a Digital Health Investment Company in...
TOKYO & SAN FRANCISCO Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce that Astellas has launched...
View ArticleClik here to view.
Astellas Reports First Quarter Financial Results of FY2016
TOKYO Astellas Pharma Inc. (TOKYO:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for the first quarter of fiscal year 2016 ending March 31, 2017...
View ArticleClik here to view.
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance • Underlying revenue grew +9.1%, driven by a +15.3% increase...
View ArticleClik here to view.
武田薬品：2016年度第1四半期の連結業績について力強いスタートで年間マネジメントガイダンスを堅持
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 2016年度第1四半期（4-6月期）の力強い業績により、年間マネジメントガイダンスを堅持...
View ArticleClik here to view.
DCAT Week规模扩大促使该年度盛会增加其纽约市会议空间
新泽西州罗宾斯维尔 (美国商业资讯)–鉴于出席人数的大幅增加和升级后商业会议空间所带来的机遇，药物、化学品和相关技术协会(DCAT)宣布，该机构将在曼哈顿中城区增设四个会场，以扩大其旗舰盛会DCAT Week（2017年3月20日-23日）的规模。DCAT Week是医药研发和生产以及相关行业领域企业的首要业务开发盛会。 DCAT...
View ArticleClik here to view.
Clik here to view.
Hoya Reports First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO: 7741) today announced financial results for the first quarter ended June 30, 2016. During the quarter, revenues totaled 115,165 million yen, representing a decline of...
View ArticleClik here to view.
Ligand Announces Multi-Program LTP Technology Licensing Agreement with...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion...
View ArticleClik here to view.
武田公布2016财年第一季度业绩，财年开局喜人，有信心实现管理层指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的第一季度业绩，有信心实现管理层指引 • 基础营收增长+9.1%，得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长。（根据报告的营收下降-2.8%，至4,340亿日元，归咎于撤资和货币影响） •...
View ArticleClik here to view.
Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate...
LONDON Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 global licensing, co-development, and commercialisation agreement (the “2011 Agreement”) regarding...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical...
View ArticleClik here to view.
Central Orthodontic Clinic: Revolution in Orthodontics Accomplished with KILBON
SEOUL, South Korea KILBON, so-called next-generation orthodontics has recently become the hottest issue as it is very innovative to correct severe dentoalveolar protrusion and hyperdivergent face at...
View ArticleClik here to view.
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical...
TOKYO & SCHAUMBURG, Ill. Shepard Vision, Inc., a Delaware corporation (the “Purchaser”) and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (the “Parent”), a joint stock...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the...
LONDON Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market,...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place...
View ArticleClik here to view.
NuGEN Technologies Announces Launch of Fusion Data Analysis Application,...
SAN CARLOS, Calif. NuGEN Technologies, Inc. today announced the availability of the Ovation Fusion Detection application, providing a data analysis tool for the Ovation Fusion Target Enrichment...
View ArticleClik here to view.
武田与Seattle Genetics发布ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)与Seattle Genetics, Inc. (NASDAQ:SGEN)今天宣布，评估ADCETRIS (brentuximab...
View ArticleClik here to view.
SoftBank Launches Second Round of ‘SoftBank Innovation Program’
TOKYO SoftBank Corp. (“SoftBank”), a subsidiary of SoftBank Group Corp. (TOKYO:9984), today announced that it launched a second round for its ‘SoftBank Innovation Program’, a program that seeks a...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスがCD30発現皮膚T細胞リンパ腫でアドセトリス（ブレンツキシマブ・ベドチン）を検討する第3相ALCANZA臨床試験の良好...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Nativis, Inc. Enters into Evaluation Agreement with Major Japan-Based...
SEATTLE Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an...
View Article